SCHEMBL5336545

SCHEMBL5336545

O=c1cc(O)c2cc(I)ccc2o1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.64
CA12 O43570 4/20 0.59
CA9 Q16790 4/20 0.59
CA1 P00915 1/20 0.59
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 4/20 0.53
KMT2A Q03164 2/20 0.53
APP P05067 4/20 0.50
MET P08581 1/20 0.44
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
MCL1 Q07820 8/20 0.41
AKR1B1 P15121 4/20 0.41
HPGD P15428 3/20 0.41
HSD17B10 Q99714 3/20 0.41
CYP3A4 P08684 2/20 0.41
THRB P10828 1/20 0.41
LMNA P02545 2/20 0.39
CYP1A2 P05177 2/20 0.39
GLA P06280 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16582394 0.85 ALDH1A1 (0.68) PIM1CA12CA9CA1ALDH1A1
SCHEMBL5341818 0.81 KDM4E (0.72) PIM1CA12CA9CA1ALDH1A1
SCHEMBL31290722 0.78 PIM1 (0.64) PIM1CA12CA9CA1ALDH1A1
SCHEMBL2490464 0.78 PIM1 (0.64) PIM1CA12CA9CA1ALDH1A1
SCHEMBL3075754 0.78 PIM1 (0.64) PIM1CA12CA9CA1ALDH1A1
SCHEMBL2761544 0.78 PIM1 (1.00) PIM1CA12CA9CA1ALDH1A1
SCHEMBL31621885 0.78 PIM1 (0.64) PIM1CA12CA9CA1ALDH1A1
SCHEMBL2492142 0.78 PIM1 (0.64) PIM1CA12CA9CA1ALDH1A1
SCHEMBL8114853 0.78 PIM1 (0.64) PIM1CA12CA9CA1ALDH1A1
SCHEMBL9640769 0.75 PIM1 (0.60) PIM1CA12CA9CA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114345-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-04-10 US disclosed
WO-2025049994-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) 2025-03-06 WO disclosed
US-7208518-B2 Substituted furochromene compounds of antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2007-04-24 US disclosed
US-20060148890-A1 Substituted furochromene compounds of antiinflammatory action PLIVA-LSTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed
EP-1648901-A1 SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP disclosed
WO-2005010006-A1 SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114345-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF EP300, CREBBP, HDAC1 PIM1 2000/4885CA12 3088/4885CA9 2265/4885
US-20060148890-A1 Substituted furochromene compounds of antiinflammatory action LTC4S, CYP11B2, CYP11B1 PIM1 4602/4885CA12 3303/4885CA9 2752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.